Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P23416
UPID:
GLRA2_HUMAN
Alternative names:
-
Alternative UPACC:
P23416; A8K0J6; B2R6I8; B7Z4F5; J3KQ59; Q53YX7; Q6ICQ0; Q99862
Background:
The Glycine receptor subunit alpha-2 plays a pivotal role in the central nervous system as a ligand-gated chloride channel. Its activation by glycine, taurine, and beta-alanine facilitates the generation of inhibitory postsynaptic currents, crucial for maintaining the balance of neuronal excitability. This receptor's involvement in synaptic plasticity and cellular responses to ethanol underscores its significance in neurophysiological processes.
Therapeutic significance:
Intellectual developmental disorder, X-linked, syndromic, Pilorge type, a condition marked by developmental delays, speech impediments, and behavioral issues, is directly linked to mutations affecting the Glycine receptor subunit alpha-2 gene. This association highlights the receptor's therapeutic potential in addressing neurodevelopmental disorders.